Human Molecular Genetics · 2001 · 214 citations · 29 references
Life SciencesGeneticsMolecular GeneticsCancer GeneticsCytogeneticsMolecular OncologyGene Fusions In CancerMolecular CytogeneticsOncogenic Fusion GenesPediatric LeukemiasAcute LeukemiasAcute Myeloid Leukemia BiologyGene Fusion Transcript AnalysisHematologic Malignancy FusionsLeukemia CytogeneticsLeukemia-associated Fusion GenesTranscriptsTranslocation-associated Leukemias
The CBP gene at 16p13 fuses to MOZ and MLL as a result of the t(8;16)(p11;p13) in acute (myelo)monocytic leukemias (AML M4/M5) and the t(11;16)(q23;p13) in treatment-related AML, respectively. We show here that a novel t(10;16)(q22;p13) in a childhood AML M5a leads to a MORF-CBP chimera. RT-PCR using MORF forward and CBP reverse primers amplified a MORF-CBP fusion in which nucleotide 3103 of MORF was fused in-frame with nucleotide 284 of CBP. Nested RT-PCR with CBP forward and MORF reverse primers generated a CBP-MORF transcript in which nucleotide 283 of CBP was fused in-frame with nucleotide 3104 of MORF. Genomic analyses revealed that the breaks were close to Alu elements in intron 16 of MORF and intron 2 of CBP and that duplications had occurred near the breakpoints. A database search using MORF cDNA enabled us to construct an exon-intron map of the MORF gene. The MORF-CBP protein retains the zinc fingers, two nuclear localization signals, the histone acetyltransferase (HAT) domain, a portion of the acidic domain of MORF and the CBP protein downstream of codon 29. Thus, the part of CBP encoding the RARA-binding domain, the CREB-binding domain, the three Cys/His-rich regions, the bromodomain, the HAT domain and the Glu-rich domains is present. In the reciprocal CBP-MORF, part of the acidic domain and the C-terminal Ser- and Met-rich regions of MORF are likely to be driven by the CBP promoter. Since both fusion transcripts were present, their exact role in the leukemogenic process remains to be elucidated.
29
Molecular cloning: A laboratory manual
Prescott L. Deininger · Analytical Biochemistry · 1990 · 86.2K citations
A Novel Fusion Between MOZ and the Nuclear Receptor Coactivator TIF2 in Acute Myeloid Leukemia
Melina Carapeti, Ricardo C.T. Aguiar, John M. Goldman et al. · Blood · 1998 · 247 citations · Full text
Medicine, Cancer Biology, Oncology +15
A Novel Fusion Between MOZ and the Nuclear Receptor Coactivator TIF2 in Acute Myeloid Leukemia
Melina Carapeti, Ricardo C.T. Aguiar, John M. Goldman et al. · Blood · 1998 · 238 citations · Full text
Medicine, Cancer Biology, Oncology +15